...
机译:发现嗜酸性呋喃[2,3- D]嘧啶衍生物作为EGFR / HER2酪氨酸激酶及其抗癌活性的双重抑制剂
Pharmaceutical Chemistry Department Faculty of Pharmacy Ain Shams University;
Pharmaceutical Chemistry Department Faculty of Pharmacy Ain Shams University;
Pharmaceutical Chemistry Department Faculty of Pharmacy Ain Shams University;
Center for Drug Discovery and Development Research Faculty of Pharmacy Ain Shams University;
Department of Pharmacology and Toxicology Faculty of Pharmacy Al-Azhar University;
Center for Drug Discovery and Development Research Faculty of Pharmacy Ain Shams University;
Pharmaceutical Chemistry Department Faculty of Pharmacy Ain Shams University;
Furopyrimidine; EGFR/HER2 kinase; In-vivoactivity; Flow cytometry; Docking study;
机译:发现嗜酸性呋喃[2,3- D]嘧啶衍生物作为EGFR / HER2酪氨酸激酶及其抗癌活性的双重抑制剂
机译:发现新的喹唑啉衍生物作为不可逆转的双EGFR / HER2抑制剂及其抗癌活动 - 第1部分
机译:新型吡唑并[3,4-d]嘧啶:设计,合成,抗癌活性,EGFR / ErbB2受体酪氨酸激酶双重抑制活性,对细胞周期和caspase-3介导的细胞凋亡的影响
机译:喹唑啉衍生物作为表皮生长因子受体 - 酪氨酸激酶(EGFR-TK)抑制剂的QSAR研究
机译:小分子酪氨酸激酶抑制剂在人结肠癌中靶向EGFR和ErbB2。
机译:拉帕替尼一种EGFR和HER2酪氨酸激酶双重抑制剂通过抑制EGFR和HER2的核转运而下调胸苷酸合酶。
机译:EGFR-HER2双重抑制剂AFATINIB在EGFR-突变体肺癌患者中获得可逆EGFR酪氨酸激酶抑制剂的抗性